The estimated Net Worth of Brian Edwin Cathers is at least $4.82 Million dollars as of 1 March 2021. Brian Cathers owns over 3,750 units of Global Blood Therapeutics stock worth over $911,054 and over the last 6 years he sold GBT stock worth over $140,294. In addition, he makes $3,767,190 as Chief Scientific Officer at Global Blood Therapeutics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Brian Cathers GBT stock SEC Form 4 insiders trading
Brian has made over 6 trades of the Global Blood Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,750 units of GBT stock worth $256,838 on 1 March 2021.
The largest trade he's ever made was exercising 7,500 units of Global Blood Therapeutics stock on 1 March 2020 worth over $513,675. On average, Brian trades about 2,582 units every 41 days since 2019. As of 1 March 2021 he still owns at least 13,302 units of Global Blood Therapeutics stock.
You can see the complete history of Brian Cathers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Cathers biography
Dr. Brian Cathers Ph.D. serves as Chief Scientific Officer of the Company. Dr. Cathers previously served as executive director and head of drug discovery at Celgene Corporation, or Celgene, from November 2015 to February 2019, and as senior director of biochemistry and structural biology at Celgene from October 2013 to November 2015. At Celegene, Dr. Cathers’ teams produced eight new development candidates and advanced five investigational drugs into clinical testing. Prior to joining Celgene, Dr. Cathers served as senior group leader and director at NewBiotics, Inc. from August 2000 to February 2004, where he oversaw enzymology and biophysical chemistry research, and was part of small team that developed a colorectal cancer drug from basic research to clinical testing. Prior to joining NewBiotics, he served as an enzymologist at Axys Pharmaceuticals. Dr. Cathers holds a B.S. in chemistry from Emporia State University and an M.S. and Ph.D. in medicinal chemistry from the University of Kansas.
What is the salary of Brian Cathers?
As the Chief Scientific Officer of Global Blood Therapeutics, the total compensation of Brian Cathers at Global Blood Therapeutics is $3,767,190. There are 1 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
How old is Brian Cathers?
Brian Cathers is 50, he's been the Chief Scientific Officer of Global Blood Therapeutics since 2019. There are 19 older and 1 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
What's Brian Cathers's mailing address?
Brian's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Global Blood Therapeutics
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
What does Global Blood Therapeutics do?
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
What does Global Blood Therapeutics's logo look like?
Complete history of Brian Cathers stock trades at Global Blood Therapeutics
Global Blood Therapeutics executives and stock owners
Global Blood Therapeutics executives and other stock owners filed with the SEC include:
-
Ted Love,
President, Chief Executive Officer, Director -
Brian Cathers,
Chief Scientific Officer -
Tricia Suvari,
Chief Legal Officer -
Jung Choi,
Chief Business and Strategy Officer -
David Johnson,
Chief Commercial Officer -
Jeffrey Farrow,
Chief Financial Officer -
Dr. Ted W. Love,
Pres, CEO & Director -
Dr. Ted W. Love M.D.,
Pres, CEO & Director -
David L. Johnson,
Chief Commercial Officer -
Jeffrey S. Farrow,
CFO & Principal Accounting Officer -
Jung E. Choi,
Chief Bus. & Strategy Officer -
Dr. Kim Smith-Whitley M.D.,
Exec. VP and Head of R&D -
Patricia Borga Suvari,
Chief Legal Officer & Sec. -
Mark Perry,
Lead Independent Director -
Scott Morrison,
Independent Director -
Wendy Yarno,
Independent Director -
Deval Patrick,
Director -
Glenn Pierce,
Independent Director -
Philip Pizzo,
Independent Director -
Willie Brown,
Independent Director -
Dawn Svoronos,
Independent Director -
Eric Fink,
Chief Human Resource Officer -
Stephanie Yao,
Sr. Director of Corp. Communications & Investor Relations -
Nazila Habibizad,
Exec. VP of Operations -
Dr. Andrej Sali Ph.D.,
Founder & Advisor -
Dr. Matthew P. Jacobson Ph.D.,
Founder & Advisor -
Dr. David R. Phillips,
Founder & Advisor -
Lesley Ann Calhoun,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Ii, L.P.Third...,
-
Michael W Bonney,
Director -
Eleanor Ramos,
Chief Medical Officer -
Kevin P Starr,
Director -
Charles J Homcy,
Director -
Robert I Tepper,
10% owner -
Rock Ventures Ii, L.P.Starr...,
-
Hing Sham,
See Remarks -
Joshua Lehrer Graiwer,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Peter Radovich,
See Remarks -
Nazila Habibizad,
See Remarks -
John Schembri,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Iii, L.P.Thir...,
-
Carrie Krehlik,
Chief Human Resources Officer -
Alexis A. Thompson,
Director -
Kim Smith Whitley,
See Remarks